Octaviani, Alessandro. "Biotechnology in Brazil: Promoting Open Innovation." Access to
Knowledge in Brazil: New Research on Intellectual Property, Innovation and Development. Ed.
Lea Shaver. London: Bloomsbury Academic, 2008. 79–102. Access to Knowledge. Bloomsbury
Collections. Web. 22 Jan. 2023. <http://dx.doi.org/10.5040/9781849660785.ch-004>.
Downloaded from Bloomsbury Collections, www.bloomsburycollections.com, 22 January
2023, 15:52 UTC.
Copyright © Lea Shaver and the contributors 2010. You may share this work for non-commercial
purposes only, provided you give attribution to the copyright holder and the publisher, and provide
a link to the Creative Commons licence.
79
CHAPTER FOUR
Biotechnology in Brazil:
Promoting Open Innovation
Alessandro Octaviani*
This chapter examines the current efforts of the Brazilian state to promote
the biotechnology sector, leveraging the nation’s immense biodiversity as a
resource for economic development. The analysis focuses on a case study
of the ONSA Network’s Genoma Program, which adopted a collaborative
approach to basic research in biotechnology. This experience may be
considered a success story in open innovation. Critical questions emerge,
however, when examining the prospects for commercial application of
these discoveries. Will scientic analysis of Brazil’s vast natural resources
propel rapid innovation in agriculture, medicine and other elds? Or will
multiplying intellectual property claims result in a “patent thicket” that
holds back development in Brazil’s biotechnology sector? Our discussion of
these issues develops in three parts:
Part one reviews the political context of the biotechnology sector’s
development in Brazil. In 2003, federal policymakers identied this hightechnology industry as a promising site for development. In 2007, a national
biotechnology policy was issued, along with a commitment to a signicant
investment in public funds.
Part two presents a case study of a foundational Brazilian experience
in biotechnology research: the Genoma Program developed by the
Organization for Nucleotide Sequencing and Analysis, or ONSA Network.
This effort demonstrated the promise of an open, collaborative approach to
biotechnology research, leveraging the “wealth of networks” to jump-start a
new eld in a developing country.
*
Doctor of Economic and Financial Law, University of São Paulo and Visiting Professor at the
Fundacão Getulio Vargas School of Economics in São Paulo. The author wishes to thank Caio
Mario Neto of FGV Law School and Jack Balkin of Yale Law School for establishing the intellectual
partnership that gave origin to this work, and to extend a special note of appreciation to Lea Shaver,
Clara Sattler Brito, Lauren Henry and Monica Guise, for their insightful, constructive and generous
intellectual contributions to the development of this chapter and for a more exceptional quality, their
great patience.
80
ACCESS TO KNOWLEDGE IN BRAZIL
Part three examines the importance of intellectual property policy for
the future of Brazil’s biotechnology sector. This part discusses the tensions
between biotechnology patenting and the opportunities for collaboration
that characterized the ONSA Network’s Genoma Program. The chapter
concludes by examining the prospects for promoting more open innovation
in the Brazilian biotechnology sector.
The Biotechnology Development Policy
The Brazilian state plays a fundamental role in shaping the eld of
biotechnology, acting as networker, nancer and producer. Highly conscious
of its position as the nation with the greatest biodiversity in the world, the
Brazilian government views biotechnology as a critical element in its global
competitiveness strategy. Although rmly committed to market-based
development, the Brazilian state’s view is that private companies must have
the support of a national innovation system to jump-start development in
this strategic sector.
According to Brazil’s 2003 Industrial, Technological and Foreign Trade
Policy – Prospectiva Consultoria Brasileira de Assuntos Internacionais
(PITCE) – “the global scenario is characterized by new economic dynamics
based on an increase in the demand for unique products and processes, made
possible by the intensive and accelerated development of new technologies
and forms of organization. This new dynamic sees innovation as the key
element for industrial and national competition growth” (Governo Federal
2003, 4). Among other measures, the 2003 economic strategy document
identied biotechnology as a key sector for development. Also in that
year, the government established the Biotechnology Competitiveness
Forum – Fórum de Competitividade de Biotecnologia – to bring together
researchers, industry and labor to dene sector-specic policy goals and
opportunities (Furlan et al. 2006). Four years later, the federal government
formally launched its Biotechnology Development Policy – Política de
Desenvolvimento da Biotecnologia (Governo Federal 2007).
In a speech announcing the new policy, President Lula encapsulated its
ambitious goals: “by holding twenty percent of all global biodiversity and vast
forests, Brazil stands out as an important country in this new development
vector. The goal of the Biotechnology Policy is to fully exploit this potential
so that in the next ten to fteen years, Brazil will rank among the ve greatest
research, services and biotechnological production centers in the world” (Lula
da Silva 2007, 3). Driving home the centrality of high technology innovation
BIOTECHNOLOGY IN BRAZIL
81
to national development aims, the President promised, “Brazil is not and
will never be again a mere supplier of raw material to the global market.
Rather, the Brazilian Growth Acceleration Program and Biotechnology
Development Policy have looked towards another direction, dening other
priorities for Brazilian development in the twenty-rst century” (ibid., 5).
In announcing its new biotechnology policy, the government was building
upon several successful experiences with publicly funded research over the
last three decades (Valle 2005). The Brazilian state’s investments in scientic
innovation have ranged from chemistry and pharmaceuticals (Vitolo 1999),
to geosciences (Assad 2000), to agriculture and environment (Bin 2004). A
point of particular national pride has been the nation’s success in developing
new biofuels to protect its energy independence and create new markets for
major crops (Ayarza 2007).
The political rhetoric surrounding the Biotechnology Development Policy
made this connection explicit. Quoting again from the president’s address:
Our objective is to take up a leadership position in [the biotechnology
eld] similar to that already assumed by the biofuel area. This has become
a partnership of indisputable success between the scientic community
and the efciency of the Brazilian entrepreneurial society. Our greatest
challenge, my friends, is to repeat this successful collaboration in
other areas of the economy and production. We must begin to produce
affordable drugs and vaccines, biodegradable plastic, develop more
effective and less polluting industrial enzymes, more nutritious food,
medicines and cosmetics from our bio-diverse environment and
techniques of environment recovery. In addition, in the future, we
must focus on biotechnology by investing in DNA sequencing research,
the neurosciences, stem cell research, nano-biotechnology, [and]
biopharmaceuticals [...]. (Lula da Silva 2007, 3)
Similar points were made in accompanying announcements from government ministers responsible for implementing the new policy (Furlan et al.
2006). These also gave more detail on how the efforts would be carried out:
[T]he Biotechnology Development Policy [...] means focusing on
innovation and the integration of research and production [...]. Efforts
and resources will be allocated for the production of vaccines and
hemo-derivatives, plus other specialized products and services to meet
82
ACCESS TO KNOWLEDGE IN BRAZIL
the demands of public health; development of processes connected to
biomass and food, cosmetics and environmental uses [...] development
of strategic agricultural and cattle raising products, and to reach
new competition and food safety levels by introducing innovations
and product differentiation to win new markets. [...] To do so, Brazil
[also] needs to address key industrial consolidation issues, from the
establishment of stable and safe regulatory boundaries to scal and
credit policies. (Furlan et al. 2006, A-3)
Within this framework, the federal government committed R$6 billion –
approximately US$3.5 billion – in public funds to support biotechnology
research and development over ten years. The government aims to have
private companies contribute an additional R$4 billion. The efforts will be
guided by two institutions. The National Biotechnology Committee – Comitê
Nacional de Biotecnologia – is composed of researchers, government ofcials
and members of civil society, including representatives of indigenous groups.
The Biotechnology Competition Forum, established in 2003, continues to
represent the interests of the business sector.
The National Biotechnology Policy reects the Brazilian state’s belief that
collaborative partnerships in scientic research and development can yield
benets for business and for society as a whole. A crucial element in this
effort is state support for basic science, which is understood to yield not only
technological discoveries necessary for product innovation, but also to serve
as a training ground for human capital – in the form of skilled researchers
and scientists – upon which this new sector depends. Although the National
Biotechnology Policy has only recently been formally announced, statesponsored research has a long tradition in Brazil including in the eld of
biotechnology. A critical evaluation of these prior experiences will shed light
on the challenges and opportunities presented as the government prepares
to expand these efforts through the National Biotechnology Policy.
An open research model for biotechnology
This section presents a case study of São Paulo’s “virtual institute” for
genomics research: the Organization for Nucleotide Sequencing and
Analysis, or ONSA Network – Rede ONSA. Launched in 1997, the ONSA
Network’s Genoma Program represents the beginning of genomics research
in Brazil. Developed in São Paulo – the state with the highest degree of
industrialization and the densest university network – the Genoma Program
BIOTECHNOLOGY IN BRAZIL
83
has tackled a series of genetic sequencing challenges over the past decade.
Through these projects, the ONSA Network was developed and technical
capacity for genomics research in Brazil greatly expanded.
The following analysis focuses on the collaborative and open dimensions
of the ONSA Network’s practices, examining whether it is possible to
characterize these efforts as consistent with an access to knowledge
approach to open innovation. This analysis will show that collaborative
practices in the biotechnology eld can promote access to knowledge across
two dimensions: broader dissemination of technical capacity, and more
democratic control over the products of basic research. The democratization
drive at the research stage may still give way to privatization later on,
however, as entrepreneurial actors seek to appropriate the downstream
benets of research.
Conception of the ONSA Network’s Genoma Program
The São Paulo State Foundation for Research Assistance – Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP) – established the
Genoma Program in 1997. The program had two objectives: rst, to discover
new biotechnological methods for improving local agriculture; and second,
to develop expertise in genomics in the State of São Paulo (Dal Poz 2000,
O Estado de São Paulo 1997). To achieve these goals, FAPESP established
a network of thirty university laboratories. These laboratories would act
as “a virtual genomics institute” to collaborate in sequencing the complete
genome of xylella fastidiosa, a bacteria responsible for signicant damage
to the region’s citrus crops (FAPESP 2008).
The ONSA Network’s Genoma Program offers an example of alternative
production models and the “wealth of networks.” According to Yochai
Benkler’s wealth of networks theory, new digital technologies facilitate
collaborative production of information goods, enabling less centralized,
less capital-intensive production models (Benkler 2006). Whereas the
traditional model for jump-starting genomics research was to establish a
single national genomics research facility, the Brazilian experiment sought
to coordinate the efforts of many smaller laboratories. This decentralized
production model was facilitated by the contributions of a distributed
network of researchers to a central data repository through the Internet.
In this way, the project’s founders sought to build comparable genomics
research capabilities, but at a lower cost and with a shorter start-up time
(Macilwaine and Neto 2000, 440).
84
ACCESS TO KNOWLEDGE IN BRAZIL
Consistent with this capacity building approach, the ONSA Network
was designed to create opportunities for researchers to receive training in
genetic sequencing techniques. The project’s announcement stated: “This
joint effort should signicantly increase the number of laboratories in the
state capable of using modern molecular biology techniques. The project
also intends to provide contemporary training in basic molecular biology to
graduate students to develop the biotechnology eld and the ‘genome culture’
in Brazil” (ONSA 1997). Even laboratories without established expertise in
molecular biology were invited to participate in the ONSA Network, provided
they submitted a clear proposal for how the skills acquired would be applied
in future research activities.
Results of the ONSA Network’s Genoma Program
In 1999 the Genoma Program achieved its original goal, producing the
world’s rst complete genomic sequence of a plant pathogen. The striking
accomplishment led to a feature in the respected scientic journal Nature
(Macilwaine & Neto 2000). The ONSA Network’s collaborative efforts,
however, did not end with the xylella fastidiosa breakthrough. Two new
goals were set in 1998: sequencing 50,000 sugar cane genes involved in plant
development and sugar content, and investigating their roles in resistance
to diseases and adverse climate and soil conditions.
The ONSA Network began its rst project with human health applications
in 1999. The Human Cancer Genome Project identied one million sequences
of Brazil’s most frequently occurring tumors before the end of the following
year. The Clinical Cancer Genome Project was later established to develop
new diagnosis and treatment methods based on these genetic insights.
Soon thereafter, ONSA Network established a project to sequence genes
of a parasite responsible for schistosomiasis, an under-researched disease
endemic to parts of Brazil.
In addition to achieving ever more ambitious sequencing goals, the
Genoma Program’s objectives in the area of technical capacity building
were also a success. At the beginning of the program, few members of the
ONSA Network had ever sequenced DNA. Five years later, more than 450
researchers had training and experience in DNA sequencing (Camargo
& Simpson 2003). The Genoma Program’s success in developing this
capacity provided the necessary human capital foundation for the national
Biotechnology Development Policy to be launched in 2007.
BIOTECHNOLOGY IN BRAZIL
85
The ONSA Network’s Genoma Program also demonstrated the feasibility
of a decentralized, network approach to advanced biotechnology research
in a developing country context. This open research model has since been
successfully applied to other public research goals, notably the BIOTA
Program, an initiative to survey and catalog the biodiversity of the state of
Sao Paulo for the purposes of environmental preservation and sustainable
exploitation.1
Given the potentially broad applications of this innovative open
research model, its contours deserve more detailed discussion. The open
research model developed by the ONSA Network has three key elements:
1) coordination between universities and public funding agencies;
2) decentralized, democratic organization of production; and 3) virtual
publication of data via the Internet.
Coordination between universities and public funding agencies
The foundation of the ONSA Network’s collaborative approach to
biotechnology research is a new system of coordination between
laboratories, facilitated by public funding. The Genoma Program’s work was
centrally guided by a ve-member steering committee, composed of three
international experts in genome sequencing and two scientists from the state
of São Paulo. A single Project DNA Coordinator was charged with generating
the fragments of the genome assigned to each laboratory for sequencing and
coordinating the ow of completed sequences from the laboratories to the
Bioinformatics Center.
Membership in the network was granted by means of a contract between
the participating laboratory and the São Paulo State Foundation for
Research Assistance (FAPESP). Under the terms of the contract, sequencing
laboratories received DNA material, equipment, and training. In return, they
were obligated to share sequence specic DNA fragments – assigned by a
1
The Biota Program, also funded by FAPESP, adopted a collaborative research approach to
mapping out the state’s biodiversity. Its organization is based on “the culture of collaborative research,” facilitated by standardization of data (Biota.org 2008). This conception is its core and in this
respect, it is a more improved and self-aware experience than its predecessor, the Genoma Program.
Taking advantage of the expertise of the previous project and the wider network of professionals
familiar with its organization and methods, the Biota Program aimed, since its beginning, to build a
broad and continuous block of information collectors, with a wide geographical and thematic reach.
The program is considered to have been a success and has involved some 500 researchers from São
Paulo, who are participating in 50 research projects. The information produced by this research effort
was instrumental in shaping later environmental policies.
86
ACCESS TO KNOWLEDGE IN BRAZIL
central research coordinator – at a prescribed standard of quality, within one
year. The resulting mapped information would be fed back into a common
repository associated with the project, which could then be accessed by any
interested party. As soon as a laboratory successfully delivered a sequence,
it could apply for a second assignment.
Decentralized, democratic organization of production
Although the research environment was stimulated by a state agency, its
actual implementation was decentralized. Individual laboratories were
responsible for their own project management. Under the terms of the
contract, laboratories received a specied payment per base pair of nished
sequence. This was set at R$4 per base pair in the initial research stage to
cover start-up costs. Of this payment, 70% was advanced before the service
was rendered, and 30% was paid upon delivery of the sequence to the BioInformatics center. Laboratories could allocate their funds for equipment,
supplies, third-party services and travel as they saw t. An incentive was
provided for efcient work, in the form of research stipends proportional to
the amount of work successfully completed. Participating laboratories could
also advance in stature according to the scale of their contributions to the
project.
The ONSA Network empowered peripheral laboratories in two ways.
First, participation in the project was open to laboratories with no
previous experience in DNA sequencing. The project funding enabled such
laboratories to purchase state-of-the-art DNA sequencing machines, and to
train their student technicians in their operation. In this way, research tools
and the relevant technical expertise spread throughout the state university
system. Second, because the participating laboratories were encouraged to
work in tandem on a common project, the joint accomplishments were of
a scope that none of the laboratories could have achieved independently.
The scale of these accomplishments helped forge a reputation for Brazilian
science in a eld previously dominated by researchers in more developed
countries.
Virtual publication of data via the Internet
The choice to create a network that was physically spread over several
research centers, with modest central coordination, was partially
motivated by limitations. There were few Brazilian researchers working in
the genomics eld before the Genoma Program, and these few researchers
BIOTECHNOLOGY IN BRAZIL
87
were spread out across several institutions. As Brazilian innovation policy
analyst Maria Ester Dal Poz has written:
The [ONSA] network allowed for links to be established between
researchers, in a scientic learning system, with the development of
genetic protocols, an exchange of information, the solving of common
problems, the adaptation and adjustment of techniques and improvements
in the productivity of DNA sequencing. The union of many laboratories
developing their own broad-scope research with a single scientic
objective was an important learning factor for generating expertise
in rened molecular and genomic biology techniques. This research
organization encourages the spreading of research throughout the whole
State, which would not have happened if a single center had been set up.
(Dal Poz 2000, 28–29)
To support such collaboration between physically, technically and
economically distant laboratories, new communications protocols were
developed to enable faster information dissemination. Centralized support
for bio-informatics was made the responsibility of the Computing Institute
of the State University of Campinas – Universidade Estadual de Campinas
(UNICAMP). This body oversaw a great evolution in the use of the ONSA
data network, which achieved full technical maturity during the Human
Cancer Genome Project. This project represents the Genoma Program’s
technical and political apex, wherein delivery of sequencing results was
combined with quality control measures to achieve a rigorously accurate
database (Kimura and Baía 2002).
In addition to meeting the communication needs of the ONSA Network,
the assembly of this IT network also led to the creation of two Brazilian bioinformatics companies. Scylla Bioinformática was established in 2002 at the
initiative of ve people who had worked on the xylella fastidiosa sequencing
and other ONSA Network projects – the company specializes in software
solutions for genomics research.2 Alellyx Applied Genomics was founded in
the same year by ve molecular biologists and informaticists involved in
the ONSA Network, with the assistance of Brazilian venture capitalists. This
company focuses specically on genomics applications for agriculture and
currently employs more than one hundred people.3
2
http://www.scylla.com.br/
3
http://www.alellyx.com.br/
88
ACCESS TO KNOWLEDGE IN BRAZIL
Learning from the ONSA Network experiment
The open research model described above created a new system of incentives
for scientic research. In the traditional market-based research model,
research is conducted within one rm, with the aim of accruing prot. In
this model, the incentive system only works if the resulting knowledge is
tightly controlled, either through secrecy or intellectual property, to ensure
that the resulting value ows back to the rm. In the traditional academic
research model, individual laboratories conduct research to advance their
reputations through publication and increase their ability to secure future
grants. In this model, laboratories may be reluctant to share any data until
the research is ready for publication. The open research model relies on a
different incentive system, wherein contributors receive payment according
to their research output, as well as valuable skills training and reputational
benets.
Within the ONSA Network model, the incentives for knowledge
production are provided through a system geared toward encouraging wide
participation, coordinated collaboration and full public access to research
outputs. This incentive structure does not require excluding others from
access to the knowledge produced, but rather rewards researchers precisely
for their contributions to a shared knowledge pool. In this model, the public
has paid for the research through the state funding agency, and the research
outcomes are returned to the public, enabling their maximum utilization by
future researchers and product developers.4 Its success demonstrates that
non-proprietary approaches to scientic research can be highly successful
and efcient.
While similarities can be noted between this open research model and the
business model of open source software, there are also signicant differences.
In the case of open source software, software developers perform workfor-hire for other private actors, motivated by market-based incentives.
No source of public funding is required to stimulate the work, as a private
market exists for these services. These developers share the knowledge
and innovations produced by their for-hire work with the larger software
development community because they have no nancial incentives not to –
their income is derived from customization services, not from ownership of
4
Note that although the investment was made by the São Paulo government, it also produced benets
to the broader Brazilian public, and to actors outside Brazil who were able to use the resulting
research for their own uses. This may argue for a greater degree of international collaboration in the
funding of open research initiatives.
BIOTECHNOLOGY IN BRAZIL
89
the underlying code – and because sharing one’s good work benets one’s
reputation. In the ONSA Network model, however, the incentives for the
original knowledge-production labor did not exist in the market. Rather,
they were provided by a public funding agency. The practice of sharing was
ensured as a contractual requirement of participation.
This model’s success shows an alternative approach to the production
of socially necessary knowledge. Here, the research is: (1) concerned
with broad problems of public welfare; (2) initiated and funded by the
state; and (3) managed in a decentralized and collaborative manner. The
ONSA Network’s unorthodox approach proved to be a viable institutional
alternative for solving knowledge problems that overwhelm the simple
rationality of individual agents. By channeling research energies through an
alternative system of incentives, a functional non-proprietary approach to
the production of knowledge was achieved. This has important implications
for the wide diffusion of socially necessary knowledge, in line with the goals
of access to knowledge.
Nevertheless, the ONSA Network case study also demonstrates some
tensions within the logic of access to knowledge. The Genoma Program’s
guiding principle was the sharing and diffusion of discoveries through
publication of all sequencing information in a public domain database.
Many other types of knowledge, however, were also generated through
this publicly funded research. In areas less politically visible and of more
immediate economic value than sequencing data, much of the knowledge
produced by the Program was privately appropriated. This was true, for
instance, of some of bio-informatics software tools mentioned above, as
well as of certain sequencing techniques developed by laboratories. Indeed,
Brazil’s 2004 Innovation Law – strongly inspired by the U.S. Bayh-Dole
Act5 – actively encouraged university researchers to seek and commercially
exploit patents on their academic discoveries (Amorim 2004). Such
privatization and enclosure of knowledge may have important consequences
5
United States Public Law 96-517, Patent and Trademark Act Amendments of 1980. The Bayh-Dole Act
set the modern framework for licensing of university discoveries in the United States. Previously, any
patentable discoveries stemming from federally funded research were to be made property of the U.S.
government, which would license them non-exclusively. Since the Bayh-Dole amendments, American
universities are allowed to retain ownership of these patents and license them at their discretion, with
revenues shared between the university and the individual inventors. Proponents of the new system
point out that it has been remarkably successful in increasing university applications for scientic
patents. Critics argue that rapidly proliferating scientic patents may ultimately harm, rather than
promote, technology innovation (Rai and Eisenberg 2002).
90
ACCESS TO KNOWLEDGE IN BRAZIL
for downstream innovation in the biotechnology sector, as will be further
explored in the nal part of this chapter.
From research to development
The ONSA Network experiment demonstrates the potential of an open
approach to biotechnology research. Brazil’s goal, however, is to be a
leader not only in biotechnology research but also in product development,
creating a new export market for biotechnology-based goods and services.
Can the open innovation model that was so successful at the research stage
also nd application in development? What implications does this have for
the National Biotechnology Development Policy, particularly as it relates
to intellectual property derived from the Brazilian biodiversity? These
questions are examined in the following part.
The emerging Brazilian biotechnology sector
In the last ten years, the biotechnology sector in Brazil has grown rapidly.
According to a recent report, “nearly 200 life science companies in the country
were identied, 40% of which were classied as biotechnology companies” 6
(Biominas 2008, 9). According to the Biominas survey, Brazilian biotechnology rms offer products in the following sectors: Agriculture (22.5%),
Reagents (21.1%), Animal Health (18.0%), Human Health (16.9%);
Environmental (14.1%), Bio-energy (4.2%) and Mixed Activities (2.8%).
Overall, the sector is young, and has an accelerating growth rate. Only 28%
of the biotechnology companies surveyed were founded before 1997; 51%
were established after 2002 (ibid.). Consistent with the youth of the sector,
a high percentage of companies were not yet protable, or were generating
only modest revenues. Only 5.4% of rms – generally the longest established
ones – had revenues greater than R$10 million (ibid.). The Biominas survey
also revealed that the biotechnology eld is concentrated in the states that
have made the greatest public investments in this eld. “The Southeastern
states, Minas Gerais (29.6%) and São Paulo (42.3%), are home to most of the
companies. Together, both states are home to seven out of ten biotechnology
companies” (ibid.).
6
The Biominas survey differentiates between biotechnology and life science companies: “Biotechnology
companies were dened as companies whose main commercial activity depends on the application of
biological organisms, biological systems or biological processes, either in internal research and development, in manufacturing or in the provision of specialist services (adopted from Nature Biotechnology). Companies that did not t into the biotechnology category but develop activities in human and
animal health, agriculture or environment were dened as life science companies” (Biominas 2008).
BIOTECHNOLOGY IN BRAZIL
91
These data reect the crucial role that incubator institutions play in
the establishment and growth of biotechnology companies. Incubators
are generally public universities or laboratories that become home to
biotechnology research projects, which ultimately have for-prot aims. Such
projects rely initially on public funding and may be dependent on the physical,
technical and personnel structure of universities or public laboratories for
several years. Over time, however, the objective is for these projects to become
independent and succeed in selling some product or service on the market.
According do the Biominas report, “Incubators play a very important role
and are responsible for a growing number of biotechnology companies in
several states throughout the country. Incubated biotech companies account
for 35.2% of the total number” (Biominas 2008, 13). Taken together, these
data reveal an industry still in its infancy, and very much dependent on state
investment for its development and growth.
The current intellectual property framework for biotechnology
The emerging Brazilian biotechnology industry will be strongly shaped by the
intellectual property regime in which it develops. Brazil’s intellectual property
regime, in turn, is strongly shaped by the global regulation of intellectual
property, particularly the terms of the World Trade Organization’s TRIPS
Agreement (WTO 1994). According to one of the authors of the current
Industrial Property7 Law (Lei 9279/96), “It is impossible to ignore the fact
that the problem [of intellectual property law] began to be analyzed by the
international community from the point of view of its implications for world
trade. The subject, the norms of which were established within the scope of a
long negotiated agreement, constitutes the principles and rules to which the
country owes an obligation, because of their international commitment and
their incorporation within the domestic legal order” (Del Nero 2004, 139).
Where the TRIPS Agreement provides exibility, however, the Brazilian
Industrial Property Law often adopts a less IP-maximalist approach than
is practiced by many other countries. The issue of patents on genetic
sequences and other issues related to biotechnology was an area of particular
controversy in the negotiations that produced the TRIPS agreement,
on which the parties ultimately “agreed to disagree.” As the Brazilian
legislature revised the Industrial Property Law to implement TRIPS in
7
Following international practice, the Brazilian intellectual property regime recognizes two categories
of intellectual property: copyright and industrial property. The latter encompasses patents, trademarks, mechanical designs and trade secrets.
92
ACCESS TO KNOWLEDGE IN BRAZIL
1996, it chose to continue a relatively restrictive approach to the scope of
allowable patents in the eld of biotechnology (Chamas 2008, 89, Del Nero
2004, 165). Under Brazilian law, no patents may be taken out on “the whole
or any part of living beings, except transgenic organisms 8 that meet the
three requirements of patentability – something that is new, an inventive
activity and an industrial application [...] and that is not a mere discovery”
(Lei 9279/96, § III, Art. 18). Also specically excluded from patentability
are “operational or surgical discoveries, techniques and methods, as well
as therapeutic or diagnostic methods for application in human or animal
bodies, and all or part of natural living beings and biological materials found
in nature, or even isolated from it, including the genome or germplasm of
any natural living being and natural biological processes.” (ibid., at Art.
10, VIII & IX). Unlike many countries, therefore, Brazil does not allow for
patenting of gene sequences.
Proposals to expand biotechnology patenting
The status quo, however, is precarious, as IP-maximalist arguments emerge
from two quarters. Advocates of the international and liberalizing policies
of the 1990s – motivated by the doctrine of New Institutional Economics –
accept the view that greater protection yields greater investment, innovation,
jobs, and general well-being. Advocates of national industry development
policies – based on the theories of neo-Schumpeterian economics and
Latin American structuralism – suggest that Brazil should provide more IP
protection to avoid having its knowledge exploited in other countries, to the
detriment of Brazil’s international competitiveness.
Members of the party that sponsored the international and liberalizing
reforms of the 1990s, the Brazilian Party of Social Democracy – Partido da
Social Democracia Brasileira (PSDB) – have already presented two bills
proposing changes to these patent ceilings. In 2003, Congressman Wilson
Santos (PSDB-MT) presented Legislative Bill 2695 to change Article 10,
IX of the Industrial Property Law to permit patenting of genetic material,
biological samples, seeds and natural biological processes. The project
was, however, removed from consideration in 2007. In 2005, however,
Congressman Antonio Thame (PSBD-SP) presented a second bill with
8
Lei 9279/96 dated May 14, 1996 – the Industrial Property Law. The only paragraph of Article 18
establishes what transgenic micro-organisms are: “[...] they are organisms, except the whole or any
part of plants and animals that, as a result of direct human intervention in their genetic composition,
express a characteristic that is not normally achievable by the species under natural conditions.”
BIOTECHNOLOGY IN BRAZIL
93
similar objectives that has already been approved in preliminary procedures
and since May 4, 2007 has been with the Environment and Sustainable
Development Committee.
The structuralist argument is put forward by scholars who maintain
that current Brazilian policy benets the corporate complexes of central
countries, at the cost of Brazilian research. By presenting restrictions to the
patenting of genetic sequences – while at the same time making sequencing
available in public international databases – Brazil may be allowing foreign
actors to patent these sequences in more lenient jurisdictions. Advocates of
this view note:
In Brazil, the rst technological results of the Sugar Cane Genome, such
as processes that reduce production costs for sugar cane and alcohol
production chains, are being negotiated with international partners. In
practice this means placing the research results in innovation systems that
are more open to genomic-based patenting of bio-technology, through
American and European patent ofces. The patent protection impediment
on genes in Brazil encourages the internationalization of genomic research
and development (Dal Poz and Barbosa 2008, 132–133).
According to these scholars, a contradiction exists in Brazil’s approach to
genetic patenting:
On the one hand a mega-diverse Brazil would agree to ght internationally
for maintaining its industrialization principle in order not to run the
risk of having material from its biodiversity used for generating genomic
innovations in other countries. On the other hand, genomic research
signicantly contributes to international gene-banks, by depositing
DNA sequences and proteomic data that increase the opportunity for
other countries, which have sufcient inventive capacity to choose the
appropriation logic that refuses the industrialization principle, to take
advantage of these resources in order to monopolize the pre-technical
knowledge phases by countries (ibid).
If advocates for relaxed patent protection standards in biotechnology win
this debate, based on either of these arguments, Brazil’s model will become
closer to that seen in most of the countries that already have signicant
biotechnology industries.
94
ACCESS TO KNOWLEDGE IN BRAZIL
Intellectual property in the Biotechnology Development Policy
The Biotechnology Development Policy also contains language setting
forth the policymakers’ understanding of how intellectual property may
be leveraged to stimulate the biotechnology sector. Decree 6041/2007
establishes a broad set of objectives related to intellectual property, listed in
Table 4.1 (Chamas 2008, 87–88).
Table 4.1 : Intellectual property objectives, Decree 6041/2007
Increase the number of biotechnological patents that are owned by Brazilians, both in Brazil and
abroad;
Encourage the development of individual and managerial skills for the effective use of intellectual
property rights;
Encourage the adoption of best practices with a view to increase in the competitiveness of Brazilian
industry;
Foster communication between research groups and industry relating to the handling and management
of intellectual property rights;
Propose the adoption of mechanisms for spreading the culture of intellectual property that involves all
players that participate;
Include legislation and the management of innovation and intellectual property in academic
biotechnology education;
Provide scientists and technicians with the necessary skills in technological management and in
strategies for protecting intellectual property and technology transfer;
Strengthen the structure of the Brazilian intellectual property system and the centers for technological
innovation;
Increase the spread of the use of the biotechnological information made available by the intellectual
property system;
Harmonize practices for managing the intellectual property of the federal and state research and
development support agencies so as to facilitate the transfer of the technologies developed by science
and technology institutions to the private sector, while preserving the rights and remuneration due to
such science and technology institutions and, when applicable, to the supporting agencies;
Harmonize intellectual property management practices with value for traditional knowledge and a
respect for the rights of traditional communities and indigenous people;
Propose the establishment of specialist courts for dealing with matters relating to intellectual property;
Stimulate the adoption of mechanisms for managing intellectual property in national science and
technology institutions so as to increase the competitiveness of Brazil’s bio-industry;
BIOTECHNOLOGY IN BRAZIL
95
Propose the adoption of mechanisms for spreading the culture of intellectual property that involves all
players that participate either directly or indirectly in innovation activities, including representatives
from the Judiciary Branch and the Government Attorney’s Ofce;
Revise and strengthen national legislation for protecting cultivated plant species, especially concerning
protecting crops for plant reproduction, strengthening the rights of patent holders and developing new
descriptors for plant crops that can be protected;
Encourage the adoption of intellectual property mechanisms for the effective protection of strains
derived from the genetic improvement of animals.
The language of these objectives reects a sympathy with those who
advocate an expansion of intellectual property protections in biotechnology.
This view is also reected in the call for a “program for accelerating protection
and patenting,” as mentioned by President Lula when launching the policy
(Lula da Silva 2007, 4–5). These indicators suggest that the Brazilian
government views greater intellectual property protection as unequivocally
desirable for the development of the biotechnology sector. The reality,
however, is more complicated.
How much intellectual property protection is too much?
As the ONSA Network’s Genoma Project shows, patent privileges are
not necessarily the most effective incentive for biotechnology research.
Other institutional and incentive arrangements can also drive research
and innovation, without excluding any parties from access to the end
results.
Too much patent protection, in fact, may stie research and development
in the biotechnology sector. The piling up of intellectual property claims
in a eld can result in what some scholars have referred to as a “tragedy
of the anticommons” (Heller 1998). The traditional phrase “tragedy of the
commons” refers to a situation in which unrestricted access to a nite resource
owned by no one – a commons – results in the exhaustion of the resource,
an ultimate loss to all (Hardin 1968). The “tragedy of the anti-commons,”
however, refers to an opposite situation, in which the proliferation of too
many ownership claims over a resource makes it impossible for anyone to use
it. This problem has also been referred to as the “patent thicket,” describing
a situation wherein an excess of intellectual property claims makes it too
96
ACCESS TO KNOWLEDGE IN BRAZIL
difcult to legally maneuver in a given eld (Shapiro 2001). Several scholars
have suggested that biotechnology may be a eld particularly prone to this
type of problem (Heller and Eisenberg 1998, Shapiro 2001, Hope 2006).
From a global perspective, life sciences research has undergone a dramatic
process of commercialization over the past three decades, driven by changes
in intellectual property law since the 1980s (Hope 2008). The result has been
a rapid increase in ling of biotechnology patents, as Hope demonstrates by
taking the U.S. patenting gures as an example. “In 1978 the USPTO granted
fewer than 20 patents in the eld of genetic engineering. By 1989 the total
number of biotechnology patents being granted each year had risen to 2,160,
increasing even further to 7,763 new patents in 2002” (Hope 2008, 35). A
similar trend is evident at the European Patent Ofce. In 1993, individuals
and corporations from the twenty-seven EU Member Countries led 920
biotechnology patent applications with the EPO. In 2003 the same countries
led 2576 such applications (Félix 2007, 5).
The increasing number of patent applications should not, by itself, be
interpreted as evidence that an anticommons has emerged (Adelman &
Deanglis 2007). Concern exists, however, because biotechnology patents
increasingly apply not only to end product inventions, but also to many
essential research tools. This greatly increases the transaction and licensing
costs associated with biotechnology research (Hope 2006). The ability to
patent genetic sequences themselves – permitted in some countries – holds
particular risk of creating an anticommons because these sequences are the
foundational point from which an entire eld of biotechnology research and
development might proceed. This presents a danger:
In theory, in a world of costless transactions, people could always avoid
commons or anticommons tragedies by trading their rights. In practice,
however, avoiding tragedy requires overcoming transaction costs,
strategic behaviors, and cognitive biases of participants, with success
more likely within close-knit communities than among hostile strangers.
Once an anticommons emerges, collecting rights into usable private
property is often brutal and slow (Heller and Eisenberg 1998, 698).
Instead of uncritically harmonizing Brazil’s intellectual property regime
with those of more developed countries, policymakers should consider
whether a lesser degree of patent protection might provide a competitive
advantage to Brazil’s emerging biotechnology industry, by reducing the
BIOTECHNOLOGY IN BRAZIL
97
costs of research and avoiding a biotechnology anticommons. This prospect
seems particularly promising in the case of Brazil where: 1) there is a past of
unorthodox practices for creating genomic science, involving public funding
and public universities with decentralized management; 2) there exists a
strong relationship between universities and companies as a result of the
biotechnology incubators; 3) there is a recently developed policy framework,
which is not yet fully dened in favor of the logic of enclosure.
In addition to carefully limiting the scope and term of genetic patents,
another way to avoid the tragedy of the anticommons is to pursue an
open source approach to biotechnology development (Hope 2004,
2006, 2008). This proposal is based on the experience of the open
source software industry, discussed in an earlier chapter in this volume.
Replicating this experience in the eld of biotechnology would require
university researchers or a public body to obtain patents on inventions,
and then subject these to a special license specifying the terms under
which other researchers and developers are free to use and build upon
that invention. The existence of clear licenses associated with existing
intellectual property dramatically reduces the transaction costs that
would otherwise be spent in contacting and contracting with the owner
or owners. This benet is magnied when – as is the case with open
source software – a substantial portion of useful inventions within a
eld have identical or compatible licenses attached. This compatibility
dramatically facilitates research and development projects that utilize
many different components to enable more complex research or develop
more sophisticated technologies.
Prospects for open innovation in Brazil’s biotechnology sector
Brazil’s current situation provides a unique opportunity for institutional
imagination and policy experimentation. At present, the Brazilian biotechnology sector is still characterized by a collaborative culture, which has
yielded visible and practical results through the ONSA Network’s Genoma
Program. Some policymaking institutions – like the Brazilian Institute of
Industrial Property, the National Economic and Social Development Bank,
and the Brazilian Industrial Development Agency – tend to adopt an IPmaximalist rhetoric, and may be suspicious of open innovation models.
Other institutions, however, may be more open to the open innovation concept.
The economic–industrial health complex, for example has countless public
players, and a well-established historical practice of sharing information,
98
ACCESS TO KNOWLEDGE IN BRAZIL
tools and products. Companies in the Brazilian biotechnology sector may
similarly see open source approaches as opportunities to free themselves from
transaction costs and successfully compete with more established foreign
players. Adopting an open source approach to biotechnology development
could provide Brazil with a competitive advantage relative to nations with
more rigid patenting systems. Because discoveries in this system would
be patented – and subjected to open licenses – this approach would also
alleviate concerns that Brazil’s natural resources and government-funded
research results end up unfairly appropriated by foreign biotechnology
companies.
An examination of the value chain of scientic research and development
yields three points of leverage where the public interest might be protected:
1) conception and funding of research, 2) publication of and access to
resulting data, and 3) patenting of technologies invented by publicly funded
actors. Each of these points of leverage offers an opportunity to promote
open innovation through appropriate licensing.
Working from the rst point of leverage, public funding for research may
be used as an opportunity to require open innovation practices. An existing
example of this approach is the requirement instituted in the United States
that all journal articles based upon research funded by the National Institutes
of Health (NIH) should be deposited into an open access digital archive.
Early data suggests the initiative has been successful (NIH Public Access
2008). In 2006, an average of fewer than 500 publications per month were
deposited. In January 2007, immediately after the mandate took effect,
more than 1000 articles were deposited. Eighteen months later, monthly
submissions to the archive topped 2500 articles (ibid). Although the NIH
initiative deals with academic publications rather than patent applications,
it is an example of how federal funding can be leveraged to ensure practices
of openness.
The second type of leverage is exercised at the point of data publication.
The International HapMap Project offers an example from the eld of
genomics research. This internationally funded project made its data on
genetic variation in global perspective available to the public at no cost. To
access the data, however, users had to agree to licensing terms that prohibited
them from using the accessed data to le genetic patents (National Human
Genome Research Institute 2004). Once the data were complete, project
managers felt they were sufciently protected from private appropriation
under the “prior art” principle alone, and opened the data to public access
BIOTECHNOLOGY IN BRAZIL
99
without licensing restrictions. This allowed the data to be integrated with
other genomic databases, ensuring that the project could achieve the full
scientic value of maximum openness (ibid.). This example illustrates both
the power of a strategic approach to licensing at the moment of access,
but also the challenges of aligning licensing regimes with the interest of
maximum openness.
Finally, an example of leverage at the point of patenting is offered by the
BiOS Initiative for Open Innovation, a project of the Australian organization
CAMBIA. This effort encourages biotechnologists to license their patented
inventions in socially responsible ways (Red Herring 2006). It also promotes
the development of open source tools for biotechnology research, and has
drafted a model license to facilitate a “protected commons” for biotechnology
researchers (BiOS 2008). These three initiatives are all targeted at the
community of individual biotechnology researchers based in universities.
Similar initiatives developed at the university level to promote licensing
regimes advancing the public interest also hold promise, although many
challenges remain (Rossini 2007).
Conclusion
As the twenty-rst century begins, Brazil seeks to transition from being an
exporter of raw materials toward a modern knowledge economy based on
innovation in high-technology elds. A central strategy for achieving this
goal is leveraging the nation’s natural resources in the area of biodiversity
to position itself among the world leaders in biotechnology research and
development.
The task of designing an appropriate intellectual property framework
to promote biotechnology research and development is a challenging one.
More intellectual property protection does not necessarily lead to more
innovation. Indeed, in the case of the biotechnology sector, there is good
reason to believe that the opposite holds true. Proliferating patent claims by
competing companies can create obstacles for biotechnology research and
development. Careful attention must be given to the structure of intellectual
property regulations to avoid stiing Brazil’s emerging biotechnology sector
in a patent thicket. Particular attention should be paid to the regulation and
promotion of licensing regimes to encourage open innovation.
The tragedy of the anticommons is a challenge facing biotechnology
globally. The success of Brazil’s biotechnology development effort will
depend in large part on the extent to which its scientists, policymakers
100
ACCESS TO KNOWLEDGE IN BRAZIL
and entrepreneurs are able to take the lead in developing new solutions,
rather than merely follow global trends. The country’s successes in this eld
to date have been achieved through open research models that generated,
organized and distributed economically valuable scientic knowledge, while
also developing and diffusing technical capacity. By realizing the “wealth
of networks,” the ONSA Network’s Genoma Program was able to transform
peripheral university facilities into centers of advanced biotechnology
research. As the National Policy on Biotechnology Development gets
underway, policymakers should consider these lessons carefully.
Bibliography
Adelman, David E. and Kathryn L. Deanglis. 2007. Patent Metrics: The Mismeasure
of Innovation in the Biotech Patent Debate. Texas Law Review, vol. 85, p. 1677.
http://ssrn.com/abstract=881842.
Amorim Páscoa, Maria Beatriz. 2004. In Search of an Innovative Environment –
the new Brazilian Innovation Law. World Intellectual Property Organization.
http://www.wipo.int/sme/en/documents/ brazil_innovation.htm#P3_103.
Assad, Ana Lucia Delgado. 2000. Biodiversidade: Institucionalização e programas
governamentais no Brasil, Tese (Doutorado em Política cientíca e tecnologógica).
Campinas, IG-Unicamp.
Ayarza, Juan Arturo Castaneda. 2007. Alternativa para aumentar a produção
mundial do etanol anidro combustível no curto prazo: o potencial dos méis
da cana, Dissertação (Mestrado em Engenharia Mecânica). Campinas, FEMUnicamp.
Benkler, Yochai. 2006. The Wealth of Networks: How Social Production Transforms
Markets and Freedom. New Haven, CN/London: Yale University Press.
Bin, Adriana. 2004. Agricultura e meio ambiente: contexto e iniciativas de pesquisa
pública, Dissertação (Mestrado em Geociência). Campinas, IG-Unicamp.
BiOS. 2008. About BiOS (Biological Open Source) Licenses and MTAs. http://www.
bios.net/daisy/bios/mta.html.
Biota.org. 2008. Histórico do Programa BIOTA-FAPESP. http://www.biota.org.br/
info/historico/resumo.
Biominas Foundation (Fundação BIOMINAS). 2008. Brazil – A Wealth of Opportunities for the Biotech Industry. Minas Gerais.
Camargo, Anamaria and Andrew Simpson. 2003. Collaborative Research Networks
Work, Journal of Clinical Investigation 112(4): 468–471.
Chamas, Cláudia. 2008. Propriedade intelectual e genômica, in Iacomini, Vanessa
(coord.). 2008. Propriedade intelectual em biotecnologia. Curitiba: Juruá.
Dal Poz, Maria Ester Soares. 2000. Da dupla à tripla hélice: o projeto genoma
Xylella, Dissertação (Mestrado em Geociência). Campinas, IG-Unicamp.
Dal Poz, Maria Ester and Denis Borges Barbosa. 2008. Incertezas e riscos no
patenteamento de biotecnologias. In: Iacomini, Vanessa (ed.) Propriedade
intelectual e biotecnologia. Curitiba: Juruá.
Del Nero, Patrícia. 2004. Propriedade intelectual – a tutela jurídica da biotecnologia,
2 ed. São Paulo: RT.
BIOTECHNOLOGY IN BRAZIL
101
FAPESP. 2008. Programa Genoma Fapesp. Accessed Aug. 25. http://www.fapesp.
br/materia/56/genoma/genoma.htm.
Félix, Bernard. 2007. Biotechnology in Europe: Patents and R&D Investments.
EuroStat: Statistics in Focus. http://epp.eurostat.ec.europa.eu/cache/ITY_
OFFPUB/KS-SF-07-100/EN/KS-SF-07-100-EN.PDF.
Furlan, Luiz Fernando, Álvares, Agenor, Pinto, Luís Carlos Guedes and Rezende,
Sérgio. 2006. Futuro certo e promissor da biotecnologia. In Folha de São Paulo,
23 de julho de 2006, p. A–3.
Furtado, Celso. 1992. Brasil – a construção interrompida. Rio de Janeiro: Paz e
Terra.
Furtado, Celso. 1984. Cultura e desenvolvimento em época de crise. Rio de Janeiro:
Paz e Terra.
Furtado, Celso. 1978. Criatividade e dependência na civilização industrial. Rio de
Janeiro: Paz e Terra.
Governo Federal. 2007. Decreto 6.041/2007 (Institui a Política de Desenvolvimento da Biotecnologia, cria o Comitê Nacional de Biotecnologia e dá
outras providências). http://www.suframa.gov.br/cba/downloads/legis_6041_
08022007.pdf.
Governo Federal. 2003. Diretrizes de Política Industrial, Tecnológica e de Comércio
Exterior, 26 de novembro de 2003, p. 4. http://www.inovacao. unicamp.br/
politicact/diretrizes-pi-031212.pdf.
Hardin, Garrett. 1968. The Tragedy of the Commons, Science, vol. 162, no. 3859, Dec. 13,
pp. 1243–1248. http://www.garretthardinsociety.org/articles/art_tragedy_of_
the_commons.html.
Heller, Michael A. 1998. The Tragedy of the Anticommons: Property in the Transition
from Marx to Markets, Harvard Law Review 111: 621.
Heller, Michael and Eisenberg, Rebecca. 1998. Can Patents Deter Innovation? The
Anticommons in Biomedical Research. Science, vol. 280, available at: http://
www.sciencemag.org/cgi/reprint/280/5364/698.pdf.
Hope, Janet. 2008. Biobazaar – the Open Source Revolution and Biotechnology.
London/Cambridge, MA: Harvard University Press.
Hope, Janet. 2006. An Introduction to Open Source Biotechnology. In: The Embassy
of Brazil, Australia (ed.). Open Source Biotechnology: A Strategy for Innovation,
Intellectual Property, and Capacity Building in Brazil – Seminar Report.
Canberra.
Hope, Janet Elizabeth. 2004. Open Source Biotechnology. Thesis submitted Dec. 23,
2004. http://ssrn.com/abstract=755244.
Kimura, Edna T. and Baía, Gilson. 2002. Rede ONSA e o Projeto Genoma Humano
do Câncer: Contribuição ao Genoma Humano, disponível em http://www.scielo.
br/scielo.php?script=sci_arttext&pid=S0004-27302002000400003.
Lula da Silva, Presidente Luiz Inácio. 2007. Discurso na cerimônia de lançamento
da Política de Biotecnologia, Palácio do Planalto, 22 de fevereiro de 2007. http://
www.info.planalto.gov.br, search by date.
Macilwaine, Colin and Neto, Ricardo. 2000. http://www.nature.com/nature/
journal/v407/n6803/full/407440a0.html.
National Human Genome Research Institute. 2004. Press Release: International
HapMap Consortium Widens Data Access. Dec. 10. http://www.nih.gov/news/
pr/dec2004/nhgri-10.htm .
102
ACCESS TO KNOWLEDGE IN BRAZIL
NIH Public Access. 2008. NIHMS Statistics, Monthly Aggregate Submission
Statistics. http://www.nihms.nih.gov/stats/index.html.
Octaviani, Alessandro. 2008. Recursos genéticos e desenvolvimento: os desaos
furtadiano e gramsciano, Tese (Doutorado em Direito). São Paulo, FaDUSP.
O Estado de São Paulo. 1997. Fapesp quer reunir os melhores cérebros. NetEstado.
11 de outubro. http://watson.fapesp.br/Imprensa/Estado02.htm.
ONSA/Organization for Nucleotide Sequencing and Analysis – Objectives, disponível
em http://watson.fapesp.br/Objectiv.htm (last accessed Aug. 3, 2009).
Rai, Arti K. and Rebecca S. Eisenberg. 2002. Bayh-Dole Reform and the Progress of
Biomedicine. Law and Contemporary Problems, vol. 66, no. 1. http://ssrn.com/
abstr=348343.
Red Herring. 2006. Open Source Biotech, Red Herring, Apr. 21, 2006. http://www.
redherring.com/Home/16473.
Rossini, Carolina. The Role of University Technology Licensing to Address the
Access and Research Gap: Analysis of some Initiatives. 2007. http://campus.
diplomacy.edu/env/scripts/Pool/GetBin.asp?IDPool=5103.
Shapiro, Carl. 2001. Navigating the Patent Thicket: Cross Licenses, Pools, and
Standard-Setting, in Innovation Policy and the Economy, 119–150. Boston: MIT
Press. SSRN: http://ssrn.com/abstract=273550.
Valle, Marcelo Gonçalves. 2005. O sistema nacional de inovação em biotecnologia
no Brasil: possíveis cenários, Tese (Doutorado em Geociência). Campinas,
IGUnicamp.
Vitolo, Michele. 1999. Perspectivas da biotecnologia no setor químico-farmcêutico,
in Farmácia e Química, no. 2. São Paulo.
WTO (World Trade Organization). 1994. Agreement on Trade-Related Aspects
of Intellectual Property Rights (TRIPS). Annex 1C, Marrakesh Agreement
Establishing the World Trade Organization. 15 April 1994. http://www.wto.org/
english/docs_e/legal_e/legal_e.htm#TRIPs.